{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sarcoma+Metastatic&page=2", "query": { "condition": "Sarcoma Metastatic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sarcoma+Metastatic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T14:42:31.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT00659360", "title": "AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Fibrous Histiocytoma", "Adult Rhabdomyosarcoma", "Dermatofibrosarcoma Protuberans", "Endometrial Stromal Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Uterine Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Uterine Carcinosarcoma", "Uterine Leiomyosarcoma" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2008-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "Rockledge, Pennsylvania", "locations": [ { "city": "Rockledge", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659360" }, { "nct_id": "NCT01506596", "title": "Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liposarcoma", "Surgically Unresectable Liposarcoma", "Metastatic Liposarcoma" ], "interventions": [ { "name": "pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vector Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2012-03", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Post Falls, Idaho + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Post Falls", "state": "Idaho" }, { "city": "Niles", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01506596" }, { "nct_id": "NCT02500797", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bone Sarcoma", "Locally Advanced Dedifferentiated Liposarcoma", "Locally Advanced Gastrointestinal Stromal Tumor", "Locally Advanced Soft Tissue Sarcoma", "Metastatic Bone Sarcoma", "Metastatic Liposarcoma", "Metastatic Soft Tissue Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Pleomorphic Liposarcoma", "Stage III Bone Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Bone Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Bone Sarcoma AJCC v7", "Stage IVB Bone Sarcoma AJCC v7", "Unresectable Bone Sarcoma", "Unresectable Dedifferentiated Liposarcoma", "Unresectable Liposarcoma", "Unresectable Malignant Gastrointestinal Stromal Tumor", "Unresectable Soft Tissue Sarcoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2015-08-13", "completion_date": "2023-04-01", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 651, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500797" }, { "nct_id": "NCT00134017", "title": "Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 142, "start_date": "2004-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134017" }, { "nct_id": "NCT00769613", "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cytomegalovirus IE-1-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 20, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769613" }, { "nct_id": "NCT06088290", "title": "Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 469, "start_date": "2023-09-21", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06088290" }, { "nct_id": "NCT01190943", "title": "DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Localized Osteosarcoma", "Metastatic Osteosarcoma", "Recurrent Osteosarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 125, "start_date": "2010-08-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01190943" }, { "nct_id": "NCT00003548", "title": "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aminocamptothecin colloidal dispersion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003548" }, { "nct_id": "NCT00118326", "title": "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": null, "start_date": "2003-08", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-07-22T14:42:31.367Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118326" } ] }